| Menorrhagia
Liletta vs Natazia
Side-by-side clinical, coverage, and cost comparison for menorrhagia.Deep comparison between: Liletta vs Natazia with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsNatazia has a higher rate of injection site reactions vs Liletta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Natazia but not Liletta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Liletta
Natazia
At A Glance
Intrauterine
Single insertion
Progestin-releasing IUS
Oral
Daily
Combined oral contraceptive
Indications
- Menorrhagia
- Menorrhagia
Dosing
Contraception Single intrauterine insertion; remove by end of eighth year; may be replaced at time of removal for continued contraception.
Menorrhagia Single intrauterine insertion; replace by end of fifth year if continued treatment of heavy menstrual bleeding is needed.
Menorrhagia One tablet daily by mouth at the same time every day, taken in the order directed on the blister pack for a 28-day sequential regimen; do not skip or delay intake by more than 12 hours.
Contraindications
- Pregnancy
- Use as post-coital contraception (emergency contraception)
- Congenital or acquired uterine anomaly, including leiomyomas, that distorts the uterine cavity
- Acute pelvic inflammatory disease (PID)
- Postpartum endometritis or infected abortion in the past 3 months
- Known or suspected uterine or cervical malignancy
- Known or suspected breast cancer or other hormone-sensitive cancer, now or in the past
- Uterine bleeding of unknown etiology
- Untreated acute cervicitis or vaginitis, including bacterial vaginosis, chlamydial or gonococcal cervical infection, or other lower genital tract infections until infection is controlled
- Acute liver disease or liver tumor (benign or malignant)
- Conditions associated with increased susceptibility to pelvic infections
- A previously inserted IUS that has not been removed
- History of hypersensitivity reaction to any component of LILETTA
- Smoking if over age 35
- Deep vein thrombosis or pulmonary embolism, current or past
- Cerebrovascular disease
- Coronary artery disease
- Thrombogenic valvular or thrombogenic rhythm diseases of the heart (e.g., subacute bacterial endocarditis with valvular disease, or atrial fibrillation)
- Inherited or acquired hypercoagulopathies
- Uncontrolled hypertension
- Diabetes mellitus with vascular disease
- Headaches with focal neurological symptoms, or migraine headaches with or without aura if over age 35
- Undiagnosed abnormal uterine bleeding
- Current or history of breast cancer which may be hormone sensitive
- Liver tumors (benign or malignant) or liver disease
Adverse Reactions
Most common (>=5%) Vulvovaginal mycotic infections, vaginal bacterial infections, acne, nausea or vomiting, headache, breast tenderness or pain, abdominal discomfort or pain, dyspareunia, anxiety, depression, pelvic discomfort or pain, dysmenorrhea, mood changes, back pain, weight increased, vaginal discharge
Serious Ectopic pregnancy, ovarian cysts, IUS perforation requiring laparoscopic surgery
Postmarketing Arterial thrombotic and venous thromboembolic events (pulmonary emboli, deep vein thrombosis, stroke), hypersensitivity reactions (rash, urticaria, angioedema), increased blood pressure, dizziness, device breakage
Most common (>=2%) Headache (including migraines), breast pain or tenderness, menstrual disorders, nausea or vomiting, acne, mood changes, increased weight
Serious Myocardial infarction, ruptured ovarian cyst, deep vein thrombosis, focal nodular hyperplasia of the liver, uterine leiomyoma, acute cholecystitis, chronic acalculous cholecystitis
Postmarketing Venous and arterial thromboembolic events, hypertension, gallbladder disease, hepatitis, hypersensitivity, fluid retention, hypertriglyceridemia, dizziness, chloasma, angioedema, erythema nodosum, erythema multiforme, gastrointestinal symptoms, vulvovaginal candidiasis
Pharmacology
Levonorgestrel-releasing intrauterine system; locally released LNG prevents pregnancy by thickening cervical mucus to inhibit sperm passage, inhibiting sperm mobility and capacitation, and altering the endometrium.
Combined oral contraceptive (COC) that lowers the risk of pregnancy primarily by suppressing ovulation; contains estradiol valerate, a synthetic prodrug of 17beta-estradiol, and dienogest, a progestin with properties of both 19-nortestosterone and progesterone derivatives.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Liletta
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (0/12)
Natazia
- Covered on 5 commercial plans
- PA (2/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Liletta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Natazia
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Liletta
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Natazia
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Liletta.
No savings programs available for Natazia.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LilettaView full Liletta profile
NataziaView full Natazia profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.